BlossomHill Therapeutics (NASDAQ:BLSM) Price Target Raised to $40.00

BlossomHill Therapeutics (NASDAQ:BLSM) had its target price hoisted by Leerink Partners from $36.00 to $40.00 in a research report released on Monday morning, Marketbeat reports. They currently have an outperform rating on the stock.

BLSM has been the topic of several other reports. Lifesci Capital initiated coverage on shares of BlossomHill Therapeutics in a research report on Tuesday, September 1st. They set an “outperform” rating and a $32.00 price objective on the stock. Guggenheim increased their target price on BlossomHill Therapeutics from $30.00 to $40.00 and gave the company a “buy” rating in a report on Monday. HC Wainwright started coverage on BlossomHill Therapeutics in a research report on Tuesday, September 1st. They issued a “buy” rating and a $35.00 target price for the company. JPMorgan Chase & Co. started coverage on BlossomHill Therapeutics in a report on Tuesday, September 1st. They set an “overweight” rating and a $28.00 price target on the stock. Finally, Zacks Research raised BlossomHill Therapeutics to a “hold” rating in a research report on Wednesday, September 2nd. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, BlossomHill Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $35.00.

BlossomHill Therapeutics Price Performance

BLSM stock opened at $22.34 on Monday. BlossomHill Therapeutics has a one year low of $15.25 and a one year high of $27.99.

BlossomHill Therapeutics (NASDAQ:BLSM) last released its earnings results on Friday, September 18th. The company reported ($8.75) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($7.91). Research analysts forecast that BlossomHill Therapeutics will post -3.86 EPS for the current fiscal year.

Insider Transactions at BlossomHill Therapeutics

In related news, General Counsel Vincent Liptak purchased 2,500 shares of the stock in a transaction dated Friday, August 7th. The shares were acquired at an average cost of $15.80 per share, for a total transaction of $39,500.00. Following the acquisition, the general counsel directly owned 109,212 shares in the company, valued at approximately $1,725,549.60. The trade was a 2.34% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director John P. Schmid purchased 6,000 shares of the stock in a transaction dated Monday, August 10th. The shares were bought at an average price of $16.00 per share, for a total transaction of $96,000.00. Following the completion of the acquisition, the director owned 6,000 shares in the company, valued at $96,000. This represents a ? increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last quarter, insiders have acquired 1,573,900 shares of company stock worth $25,181,900.

BlossomHill Therapeutics Company Profile

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.